Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Neuroscience
AbbVie buys up Cerevel for $8.7 billion
by Laura Howes
December 17, 2023
| A version of this story appeared in
Volume 101, Issue 41
In its second acquisition unveiled in less than a week, AbbVie will buy Cerevel Therapeutics for $8.7 billion. On Nov. 30, AbbVie announced the purchase of ImmunoGen for $10.1 billion (see page 10). Massachusetts-based Cerevel was founded in 2019 as a home for Pfizer’s discontinued neuroscience program and brings with it emraclidine, a late-stage antipsychotic for treating schizophrenia. Cerevel also has several clinical-stage molecules for treating neurological and other psychiatric conditions.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X